Asad Iqbal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Asad Iqbal has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Fatima Sajjad
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
5 shared publications - Abdullah Afridi
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
4 shared publications - Fazia Khattak
Department of Medicine, Khyber Medical College, Peshawar, Pakistan
4 shared publications - Muhammad Abdullah Ali
Khyber Medical College Peshawar Pakistan
4 shared publications - Umama Alam
Khyber Medical College, Peshawar, Pakistan
4 shared publications - Iqra Shahid
King Edward Medical University, Lahore, Pakistan
3 shared publications
Latest Publications
- Open Access
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e050299
Valve‐in‐Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement: Meta‐Analysis of Early and Late Outcomes
Background: Bioprosthetic mitral valve degeneration is traditionally treated with redo surgical mitral valve replacement (redo‐SMVR), but valve‐in‐valve transcatheter mitral valve replacement (ViV‐TMVR) offers a less invasive alternative. Methods: Systematic review and meta‐analysis of studies comparing ViV‐TMVR and redo‐SMVR. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane databases (inception to September 2025) were searched. Meta‐analyses were conducted with random‐effects models to assess patient‐relevant outcomes; Kaplan–Meier‐derived time‐to‐event data were pooled to assess late outcomes. Results: Thirteen observational studies met our eligibility criteria, including 15 941 patients (ViV‐TMVR: 5465; redo‐SMVR: 10476). In comparison with redo‐SMVR, ViV‐TMVR was associated with lower risk of in‐hospital mortality (risk ratio [RR], 0.72 [95% CI, 0.57–0.90]; P =0.004), stroke (RR, 0.49 [95% CI, 0.29–0.83]; P =0.008), bleeding (RR, 0.43 [95% CI, 0.20–0.94]; P =0.035), acute kidney injury (RR, 0.57 [95% CI, 0.42–0.77]; P P P P =0.256); however, the landmark analysis revealed that ViV‐TMVR was associated with lower risk of death in the initial 6 months (HR, 0.69 [95% CI, 0.58–0.83]; P P <0.001). Conclusions: In patients amenable to ViV‐TMVR, this procedure shows a lower initial risk of death and complications, but higher mortality after 6 months in comparison with redo‐SMVR. These findings highlight the importance of striking a balance between upfront surgical risk and estimated life expectancy when selecting interventions.
- 5 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (9) , e050299
Open AccessValve‐in‐Valve Transcatheter Mitral Valve Replacement Versus Redo Surgical Mitral Valve Replacement: Meta‐Analysis of Early and Late Outcomes
Background: Bioprosthetic mitral valve degeneration is traditionally treated with redo surgical mitral valve replacement (redo‐SMVR), but valve‐in‐valve transcatheter mitral valve replacement (ViV‐TMVR) offers a less invasive alternative. Methods: Systematic review and meta‐analysis of studies comparing ViV‐TMVR and redo‐SMVR. PubMed/MEDLINE, EMBASE, Web of Science, and Cochrane databases (inception to September 2025) were searched. Meta‐analyses were conducted with random‐effects models to assess patient‐relevant outcomes; Kaplan–Meier‐derived time‐to‐event data were pooled to assess late outcomes. Results: Thirteen observational studies met our eligibility criteria, including 15 941 patients (ViV‐TMVR: 5465; redo‐SMVR: 10476). In comparison with redo‐SMVR, ViV‐TMVR was associated with lower risk of in‐hospital mortality (risk ratio [RR], 0.72 [95% CI, 0.57–0.90]; P =0.004), stroke (RR, 0.49 [95% CI, 0.29–0.83]; P =0.008), bleeding (RR, 0.43 [95% CI, 0.20–0.94]; P =0.035), acute kidney injury (RR, 0.57 [95% CI, 0.42–0.77]; P P P P =0.256); however, the landmark analysis revealed that ViV‐TMVR was associated with lower risk of death in the initial 6 months (HR, 0.69 [95% CI, 0.58–0.83]; P P <0.001). Conclusions: In patients amenable to ViV‐TMVR, this procedure shows a lower initial risk of death and complications, but higher mortality after 6 months in comparison with redo‐SMVR. These findings highlight the importance of striking a balance between upfront surgical risk and estimated life expectancy when selecting interventions.
- 14 March 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (1) , 42-57.e19
To regress or not to regress? Outcomes of aneurysm sac behavior after endovascular aortic aneurysm repair: A systematic review and meta-analysis
- 14 March 2026
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 84 (1) , 42-57.e19
To regress or not to regress? Outcomes of aneurysm sac behavior after endovascular aortic aneurysm repair: A systematic review and meta-analysis
- Open Access
- 5 March 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 27
Burr hole craniostomy versus minicraniotomy for chronic subdural hematoma: an updated systematic review and meta-analysis
Background: Chronic subdural hematoma (CSHD) is a common neurological disorder, especially in older people and those on anticoagulant therapy, with incidences of 58 per 100,000 and 80 per 100,000 annually in those individuals over 65 and 75 years, respectively. It is caused by tearing of bridging veins after a minor head injury , presenting with signs and symptoms such as headache , gait disturbance , cognitive decline , hemiparesis , and even unconsciousness . The mortality rate for treated CSDH patients is relatively low, (2–5%) but can be significantly higher in older and medically frail patients, especially those with delayed diagnosis and recurrent hematomas. Objective: This systematic review and meta-analysis aimed to compare the safety, effectiveness, and perioperative outcomes of burr hole craniostomy [BHC] and minicraniotomy [MC] for the treatment of CSDH. Methods: PubMed, Embase, and Cochrane databases were systematically searched via relevant keywords from inception until July 12, 2025. A total of sixteen studies were included after the final screening. Outcomes were reported as the recurrence rate, reoperation rate, operation duration, mortality, postoperative complications, rate of good outcome, etc. Heterogeneity was assessed via I 2 (I > 50%=significant heterogeneity). Statistical calculations were performed via Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p value of < 0.05 indicating statistical significance. Results: This meta-analysis included 15 observational studies and 1 RCT with a total of 4352 patients. Compared with MC, BHC was associated with a significantly lower reoperation rate (RR: 0.53, 95% 0.32 to 0.85; P = 0.009) and shorter operation duration (RR: -20.15, 95% CI: -28.99 to -11.31; P < 0.00001). However, there was no statistically significant difference between the groups in terms of the recurrence rate (RR: 0.69, 95% CI: 0.480.99, P = 0.05), mortality rate (RR:1.07, 95% CI: 0.741.54, P = 0.72), rate of good outcomes (RR:1.20, 95% CI: 0.991.46, P = 0.07), postoperative complications (RR:0.68, 95% CI: 0.441.06, P = 0.09), MGS score (RR: -0.02, 95% CI: -0.260.22, P = 0.87) or mark Walder score (RR: 1.06, 95% CI: 0.951.18, P = 0.29). Conclusion: CSHD, BHC, and MC offered similar clinical results. BHC, however, has benefits in terms of a shorter operative time and a lower reoperation rate.
- 5 March 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 27
Open AccessBurr hole craniostomy versus minicraniotomy for chronic subdural hematoma: an updated systematic review and meta-analysis
Background: Chronic subdural hematoma (CSHD) is a common neurological disorder, especially in older people and those on anticoagulant therapy, with incidences of 58 per 100,000 and 80 per 100,000 annually in those individuals over 65 and 75 years, respectively. It is caused by tearing of bridging veins after a minor head injury , presenting with signs and symptoms such as headache , gait disturbance , cognitive decline , hemiparesis , and even unconsciousness . The mortality rate for treated CSDH patients is relatively low, (2–5%) but can be significantly higher in older and medically frail patients, especially those with delayed diagnosis and recurrent hematomas. Objective: This systematic review and meta-analysis aimed to compare the safety, effectiveness, and perioperative outcomes of burr hole craniostomy [BHC] and minicraniotomy [MC] for the treatment of CSDH. Methods: PubMed, Embase, and Cochrane databases were systematically searched via relevant keywords from inception until July 12, 2025. A total of sixteen studies were included after the final screening. Outcomes were reported as the recurrence rate, reoperation rate, operation duration, mortality, postoperative complications, rate of good outcome, etc. Heterogeneity was assessed via I 2 (I > 50%=significant heterogeneity). Statistical calculations were performed via Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p value of < 0.05 indicating statistical significance. Results: This meta-analysis included 15 observational studies and 1 RCT with a total of 4352 patients. Compared with MC, BHC was associated with a significantly lower reoperation rate (RR: 0.53, 95% 0.32 to 0.85; P = 0.009) and shorter operation duration (RR: -20.15, 95% CI: -28.99 to -11.31; P < 0.00001). However, there was no statistically significant difference between the groups in terms of the recurrence rate (RR: 0.69, 95% CI: 0.480.99, P = 0.05), mortality rate (RR:1.07, 95% CI: 0.741.54, P = 0.72), rate of good outcomes (RR:1.20, 95% CI: 0.991.46, P = 0.07), postoperative complications (RR:0.68, 95% CI: 0.441.06, P = 0.09), MGS score (RR: -0.02, 95% CI: -0.260.22, P = 0.87) or mark Walder score (RR: 1.06, 95% CI: 0.951.18, P = 0.29). Conclusion: CSHD, BHC, and MC offered similar clinical results. BHC, however, has benefits in terms of a shorter operative time and a lower reoperation rate.
- Open Access
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1849-1860
Intensive versus standard blood pressure management after endovascular therapy in acute ischemic stroke: a systematic review and meta-analysis
Endovascular thrombectomy (EVT) has improved the therapy of acute ischemic stroke, patients still have functional impairments after reperfusion. This updated meta-analysis assesses whether intense blood pressure (BP) management following successful EVT enhances results and reduces problems associated with reperfusion. PubMed, Embase, and Cochrane databases were systematically searched using relevant keywords from inception until July 2025. A total of five studies were included after final screening. Outcomes were reported as excellent clinical outcomes, functional independence, all-cause mortality at 90 days, any intracranial hemorrhage within 24 h, etc. Interstudy heterogeneity was assessed using I 2 and X 2 statistics ( I 2 > 50% = significant heterogeneity). Statistical calculations used Review Manager 5.4.1, with a P -value of P = 0.03) and functional independence (mRS modified Rankin Scale 0–2) was both markedly enhanced by intensive BP control (RR = 0.82; 95% CI: 0.74–0.91; P = 0.0002). It did not, however, have a significant effect on all-cause death at 90 days, symptomatic or any cerebral bleeding, stroke recurrence, or excellent clinical outcomes (mRS 0–1). A significant correlation was seen between a greater incidence of hypotensive episodes and severe BP lowering (RR = 1.77; P < 0.00001). It also raises the risk of hypotension without reducing the danger of hemorrhage or death. Following EVT, intense BP control may enhance early neurological results and functional independence, but it also raises the risk of hypotension without reducing death or hemorrhage.
- 20 January 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (2) , 1849-1860
Open AccessIntensive versus standard blood pressure management after endovascular therapy in acute ischemic stroke: a systematic review and meta-analysis
Endovascular thrombectomy (EVT) has improved the therapy of acute ischemic stroke, patients still have functional impairments after reperfusion. This updated meta-analysis assesses whether intense blood pressure (BP) management following successful EVT enhances results and reduces problems associated with reperfusion. PubMed, Embase, and Cochrane databases were systematically searched using relevant keywords from inception until July 2025. A total of five studies were included after final screening. Outcomes were reported as excellent clinical outcomes, functional independence, all-cause mortality at 90 days, any intracranial hemorrhage within 24 h, etc. Interstudy heterogeneity was assessed using I 2 and X 2 statistics ( I 2 > 50% = significant heterogeneity). Statistical calculations used Review Manager 5.4.1, with a P -value of P = 0.03) and functional independence (mRS modified Rankin Scale 0–2) was both markedly enhanced by intensive BP control (RR = 0.82; 95% CI: 0.74–0.91; P = 0.0002). It did not, however, have a significant effect on all-cause death at 90 days, symptomatic or any cerebral bleeding, stroke recurrence, or excellent clinical outcomes (mRS 0–1). A significant correlation was seen between a greater incidence of hypotensive episodes and severe BP lowering (RR = 1.77; P < 0.00001). It also raises the risk of hypotension without reducing the danger of hemorrhage or death. Following EVT, intense BP control may enhance early neurological results and functional independence, but it also raises the risk of hypotension without reducing death or hemorrhage.
- 14 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (2) , e0415
Sirolimus-Coated Versus Paclitaxel-Coated Balloons for Coronary Artery Disease: A Grade Assessed Systematic Review and Meta-Analysis
Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, their comparative safety and efficacy remain uncertain. PubMed, Embase, and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 randomized controlled trials and 4 observational cohort studies) were included, comprising 3633 participants overall. The primary outcomes assessed were target lesion revascularization and target lesion failure. Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I ² and X ² statistics ( I ²>50% = significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical analysis was conducted using R software and RStudio (version 4.4.2), with a P value of < 0.05 indicating statistical significance. This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon [sirolimus-coated balloon (SCB)] angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure [risk ratio (RR), 1.08, 95% CI, 0.90–1.29, P = 0.36] or target lesion revascularization (RR, 1.16, 95% CI, 0.98–1.37, P = 0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group’s minimal lumen diameter was significantly smaller than that of the PCB group (MD, −0.08 mm, 95% CI, −0.14 to −0.01, P = 0.02). In treating coronary in-stent restenosis, SCB and PCBs show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.
- 14 January 2026
- Published by Wolters Kluwer Health in Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine
- Vol. 25 (2) , e0415
Sirolimus-Coated Versus Paclitaxel-Coated Balloons for Coronary Artery Disease: A Grade Assessed Systematic Review and Meta-Analysis
Despite advances in percutaneous coronary procedures, in-stent restenosis remains a significant challenge. Although sirolimus- and paclitaxel-coated balloons are promising alternatives, their comparative safety and efficacy remain uncertain. PubMed, Embase, and Cochrane databases were searched using relevant keywords from inception until August 2025. A total of 11 studies (7 randomized controlled trials and 4 observational cohort studies) were included, comprising 3633 participants overall. The primary outcomes assessed were target lesion revascularization and target lesion failure. Meanwhile, the Secondary outcomes included stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, survival, binary restenosis, and angiographic endpoints (acute gain, diameter stenosis, in-segment late lumen loss, in-lesion late lumen loss, and in-segment minimal lumen diameter). Interstudy heterogeneity was assessed using I ² and X ² statistics ( I ²>50% = significant heterogeneity). Interstudy heterogeneity was low for most outcomes, including all primary clinical endpoints, with moderate heterogeneity observed only for select angiographic measures (notably in-segment late lumen loss and diameter stenosis). Statistical analysis was conducted using R software and RStudio (version 4.4.2), with a P value of < 0.05 indicating statistical significance. This meta-analysis examined studies that compared paclitaxel-coated balloon (PCB) versus standard balloon [sirolimus-coated balloon (SCB)] angioplasty. Regarding primary outcomes, there were no notable variations in target lesion failure [risk ratio (RR), 1.08, 95% CI, 0.90–1.29, P = 0.36] or target lesion revascularization (RR, 1.16, 95% CI, 0.98–1.37, P = 0.08). With all aggregated estimates being nonsignificant, secondary outcomes such as stent thrombosis, all-cause mortality, myocardial infarction, major adverse cardiovascular events, and survival were similar between groups. Angiographic endpoints revealed no discernible variations in late lumen loss (in-lesion and in-segment), acute gain, or diameter stenosis. Nonetheless, the SCB group’s minimal lumen diameter was significantly smaller than that of the PCB group (MD, −0.08 mm, 95% CI, −0.14 to −0.01, P = 0.02). In treating coronary in-stent restenosis, SCB and PCBs show similar overall safety and effectiveness; lesion-specific angiographic variations indicate that customized selection may improve patient outcomes.
- 29 December 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (4) , 980-992
Efficacy and safety of intravenous tirofiban pre-operatively as an adjunct to endovascular thrombectomy in ischemic stroke: a grade-assessed systematic review and Meta-Analysis
Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a significant cause of disability and mortality. While endovascular thrombectomy (EVT) is the standard treatment, microvascular reperfusion remains a challenge. Although there is mixed information about the safety and effectiveness of tirofiban, a glycoprotein IIb/IIIa inhibitor, it may improve perfusion when administered before EVT. Its effects on risks and functional outcomes, including symptomatic intracranial hemorrhage (sICH), are investigated in this meta-analysis. We systematically searched PubMed, Embase, and Cochrane from inception to July 2025 for randomized controlled trials (RCTs) and Cohorts comparing pre-EVT tirofiban with EVT alone in LVO stroke. Primary outcomes were 90-day functional independence and the ordinal shift in mRS. Secondary outcomes included mortality and symptomatic intracerebral hemorrhage. Six Studies (1,664 patients) were included. Tirofiban did not significantly improve 90-day functional independence (RR: 1.09, 95% CI: 0.88–1.36; p = 0.44; I² = 62%) or ordinal mRS (MD: 0.06, 95% CI: -0.15 to 0.27; p = 0.58; I² = 0%). Mortality was similar between groups (RR: 0.75, 95% CI: 0.54–1.06; p = 0.11; I² = 0%). sICH risk was also comparable (RR: 0.83, 95% CI: 0.46–1.51; p = 0.55; I² = 28%). Pre-procedural tirofiban did not significantly raise the risk of sICH, improve functional outcomes, or lower death in LVO stroke patients having EVT. Although additional research may improve patient selection, these results point to limited value for routine tirofiban administration before EVT. Keypoints Pre-EVT tirofiban does not significantly improve 90-day functional outcomes in AIS due to LVO. No significant benefit was observed in ordinal modified Rankin Scale scores. Mortality and risk of symptomatic intracranial hemorrhage were similar between tirofiban and control groups. Heterogeneity was moderate to low, and findings were consistent across study types. Future studies should explore optimal patient selection, dosing strategies, and timing to identify potential subgroups that may benefit from pre-EVT tirofiban. Graphical abstract
- 29 December 2025
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 59 (4) , 980-992
Efficacy and safety of intravenous tirofiban pre-operatively as an adjunct to endovascular thrombectomy in ischemic stroke: a grade-assessed systematic review and Meta-Analysis
Acute ischemic stroke (AIS) due to large vessel occlusion (LVO) is a significant cause of disability and mortality. While endovascular thrombectomy (EVT) is the standard treatment, microvascular reperfusion remains a challenge. Although there is mixed information about the safety and effectiveness of tirofiban, a glycoprotein IIb/IIIa inhibitor, it may improve perfusion when administered before EVT. Its effects on risks and functional outcomes, including symptomatic intracranial hemorrhage (sICH), are investigated in this meta-analysis. We systematically searched PubMed, Embase, and Cochrane from inception to July 2025 for randomized controlled trials (RCTs) and Cohorts comparing pre-EVT tirofiban with EVT alone in LVO stroke. Primary outcomes were 90-day functional independence and the ordinal shift in mRS. Secondary outcomes included mortality and symptomatic intracerebral hemorrhage. Six Studies (1,664 patients) were included. Tirofiban did not significantly improve 90-day functional independence (RR: 1.09, 95% CI: 0.88–1.36; p = 0.44; I² = 62%) or ordinal mRS (MD: 0.06, 95% CI: -0.15 to 0.27; p = 0.58; I² = 0%). Mortality was similar between groups (RR: 0.75, 95% CI: 0.54–1.06; p = 0.11; I² = 0%). sICH risk was also comparable (RR: 0.83, 95% CI: 0.46–1.51; p = 0.55; I² = 28%). Pre-procedural tirofiban did not significantly raise the risk of sICH, improve functional outcomes, or lower death in LVO stroke patients having EVT. Although additional research may improve patient selection, these results point to limited value for routine tirofiban administration before EVT. Keypoints Pre-EVT tirofiban does not significantly improve 90-day functional outcomes in AIS due to LVO. No significant benefit was observed in ordinal modified Rankin Scale scores. Mortality and risk of symptomatic intracranial hemorrhage were similar between tirofiban and control groups. Heterogeneity was moderate to low, and findings were consistent across study types. Future studies should explore optimal patient selection, dosing strategies, and timing to identify potential subgroups that may benefit from pre-EVT tirofiban. Graphical abstract
- Open Access
- 10 September 2025
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 40 (1) , 1-17
Efficacy and safety of indocyanine green fluorescence imaging in colorectal cancer: a systematic review and meta-analysis of randomized controlled trials
Background: The primary treatment for colorectal cancer, which is very prevalent, is surgery. Anastomotic leaking poses a significant risk following surgery. Intestinal perfusion can be objectively and instantly assessed with indocyanine green fluorescence imaging, which may lower leakage rates and enhance surgical results. Methods: PubMed, Embase, and Web of Science databases were systematically searched using relevant keywords from inception until 5th of March 2025. Eight studies were included after final screening. Outcomes were reported as overall anastomotic leakage, wound infection, paralytic ileus, mechanical ileus, and post-operative hospital stay. Interstudy heterogeneity was assessed using I 2 and X 2 statistics (I 2 > 50% = significant heterogeneity). Statistical calculations were performed using Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p-value of < 0.05 indicating statistical significance. Results: This meta-analysis includes 4047 patients from eight investigations (2026 indocyanine green (ICG) group, 2021 non-ICG group). Overall anastomotic leak risk was considerably decreased with ICG use (risk ratio (RR) = 0.66; 95% CI: 0.54–0.81; p < 0.0001) and showed no heterogeneity (I 2 = 0%). There was no heterogeneity (I 2 = 0%) in the Grade A leakage occurrence, which was considerably lower in the ICG group (RR = 0.34; 95% CI: 0.16–0.72; p = 0.005). With little heterogeneity (I 2 = 8.6%), combined leakage grades also supported ICG use (RR = 0.54; 95% CI: 0.35–0.84; p = 0.006). ICG was associated with a substantial decrease in Clavien–Dindo Grade I complications (RR = 0.67; 95% CI: 0.49–0.92; p = 0.01) without heterogeneity (I 2 = 0%). Initial postoperative hospital stays, mechanical ileus, paralytic ileus, and abdominal bleeding did not differ significantly. Although there was no heterogeneity (I 2 = 0%), sensitivity analysis showed that the ICG group had a substantially longer postoperative stay (MD = 0.27; 95% CI 0.05–0.49; p = 0.02) and significantly fewer wound infections (RR = 0.17; 95% CI 0.04–0.76; p = 0.02). With noteworthy heterogeneity (I 2 = 70%), the ICG group’s operating time was significantly longer (MD = 8.26 min; 95% CI 0.52–16.00; p = 0.04). Conclusion: Although indocyanine green fluorescence imaging may marginally lengthen the recovery period and duration of operation, it dramatically lowers anastomotic leakage and wound infections following colorectal surgery, enhancing results.
- 10 September 2025
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 40 (1) , 1-17
Open AccessEfficacy and safety of indocyanine green fluorescence imaging in colorectal cancer: a systematic review and meta-analysis of randomized controlled trials
Background: The primary treatment for colorectal cancer, which is very prevalent, is surgery. Anastomotic leaking poses a significant risk following surgery. Intestinal perfusion can be objectively and instantly assessed with indocyanine green fluorescence imaging, which may lower leakage rates and enhance surgical results. Methods: PubMed, Embase, and Web of Science databases were systematically searched using relevant keywords from inception until 5th of March 2025. Eight studies were included after final screening. Outcomes were reported as overall anastomotic leakage, wound infection, paralytic ileus, mechanical ileus, and post-operative hospital stay. Interstudy heterogeneity was assessed using I 2 and X 2 statistics (I 2 > 50% = significant heterogeneity). Statistical calculations were performed using Review Manager 5.4.1 (The Cochrane Collaboration, Copenhagen, Denmark), with a p-value of < 0.05 indicating statistical significance. Results: This meta-analysis includes 4047 patients from eight investigations (2026 indocyanine green (ICG) group, 2021 non-ICG group). Overall anastomotic leak risk was considerably decreased with ICG use (risk ratio (RR) = 0.66; 95% CI: 0.54–0.81; p < 0.0001) and showed no heterogeneity (I 2 = 0%). There was no heterogeneity (I 2 = 0%) in the Grade A leakage occurrence, which was considerably lower in the ICG group (RR = 0.34; 95% CI: 0.16–0.72; p = 0.005). With little heterogeneity (I 2 = 8.6%), combined leakage grades also supported ICG use (RR = 0.54; 95% CI: 0.35–0.84; p = 0.006). ICG was associated with a substantial decrease in Clavien–Dindo Grade I complications (RR = 0.67; 95% CI: 0.49–0.92; p = 0.01) without heterogeneity (I 2 = 0%). Initial postoperative hospital stays, mechanical ileus, paralytic ileus, and abdominal bleeding did not differ significantly. Although there was no heterogeneity (I 2 = 0%), sensitivity analysis showed that the ICG group had a substantially longer postoperative stay (MD = 0.27; 95% CI 0.05–0.49; p = 0.02) and significantly fewer wound infections (RR = 0.17; 95% CI 0.04–0.76; p = 0.02). With noteworthy heterogeneity (I 2 = 70%), the ICG group’s operating time was significantly longer (MD = 8.26 min; 95% CI 0.52–16.00; p = 0.04). Conclusion: Although indocyanine green fluorescence imaging may marginally lengthen the recovery period and duration of operation, it dramatically lowers anastomotic leakage and wound infections following colorectal surgery, enhancing results.
- Open Access
- 1 April 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 58, 101651
Outcomes of transcatheter vs surgical aortic valve replacement in pre-existing chronic liver disease patients: A meta-analysis of observational studies
- 1 April 2025
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 58, 101651
Open AccessOutcomes of transcatheter vs surgical aortic valve replacement in pre-existing chronic liver disease patients: A meta-analysis of observational studies